Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mayinglong Musk Hemorrhoids Ointment (second-generation) is a Traditional Chinese Medicine (TCM) topical formulation developed by Wuhan Mayinglong Pharmaceutical Group for the treatment of mixed hemorrhoids, internal hemorrhoids, and anal fissures. This multi-ingredient ointment is an optimized version of the classic Mayinglong formula, containing active components such as artificial musk, artificial bezoar, pearl, borneol, amber, calamine, and borax. It exerts its therapeutic effects through a combination of anti-inflammatory, analgesic, and hemostatic actions. Specifically, it inhibits pro-inflammatory cytokines to reduce swelling, utilizes borneol to provide a cooling analgesic effect via TRPM8 receptors, and employs mineral components like calamine as astringents to promote tissue regeneration and reduce edema. The second-generation designation often refers to a refined formulation used in clinical trials to demonstrate superior efficacy or safety profiles in specific patient populations, such as those with internal hemorrhoids presenting with wind-injury of the intestinal collaterals (a TCM syndrome).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mayinglong Musk Hemorrhoids Ointment (second-generation).